SCHEMBL30765740

SCHEMBL30765740

CCCCOC(=O)Cn1c([S+](C)[O-])ncc(Br)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
LMNA P02545 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 4/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 3/20 0.40
ALOX15 P16050 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
ESR1 P03372 1/20 0.34
CNR1 P21554 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
APAF1 O14727 1/20 0.33
USP2 O75604 1/20 0.33
HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765839 0.83 MEN1 (0.49) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL30765661 0.80 MEN1 (0.48) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL30766020 0.78 MEN1 (0.46) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL30765447 0.76 L3MBTL1 (0.65) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL30765514 0.76 ALDH1A1 (0.48) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL30766019 0.74 LMNA (0.54) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL30765592 0.73 L3MBTL1 (0.50) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL30766038 0.70 KMT2A (0.50) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL6649823 0.67 MEN1 (0.44) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL3649935 0.66 KMT2A (0.48) MEN1KMT2ALMNAL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed